

File No.- BMSIC/40030/525-2025/25

दिनांक:- 02/04/2025

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, बिहार पटना


BMSICL की निविदा संख्या- BMSIC/DRUGS/25-02 से संबंधित प्राप्त ई-निविदाओं के तकनीकी मूल्यांकन विवरणी पर साक्ष्य सहित दावा/आपत्ति की माँग संबंधी सूचना

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, द्वारा औषधियों की अधिप्राप्ति हेतु ई-निविदा (निविदा संख्या- **BMSIC/DRUGS/25-02**) आमंत्रित की गई थी, जिसके आलोक में निर्धारित समय सीमा के अन्तर्गत कुल 07 (सात) ई-निविदा प्राप्त हुई। उक्त 07 (सात) ई-निविदा के दस्तावेजों के प्राथमिक तकनीकी मूल्यांकन के उपरान्त तैयार की गई तकनीकी मूल्यांकन विवरणी के दावा/आपत्ति के आमंत्रण हेतु BMSICL के **website (www.bmsicl.gov.in)** एवं e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** पर अपलोड की गई है।

निविदा में भाग लेने वाले निर्माता संस्थान अथवा अन्य आपूर्तिकर्ता अपलोड किये गए उपर्युक्त तकनीकी मूल्यांकन प्रपत्र में किसी प्रकार की विसंगति पाये जाने की स्थिति में, साक्ष्य सहित अपना दावा/आपत्ति दिनांक 08/04/2025 के अपराह्न 05:00 बजे तक केवल e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** के माध्यम से कर सकते हैं।

e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** के अलावा अन्य किसी माध्यम से प्राप्त किसी प्रकार के दावा/आपत्ति पर कोई विचार नहीं किया जायेगा।

अनुलग्नक- यथोक्त


(हरेन्द्र राम)
महाप्रबंधक (अधिप्राप्ति)

ज्ञापांक:- BMSIC/40030/525-2024/25

दिनांक:- 02/04/2025

प्रतिलिपि :- प्रबंधक (सिस्टम) एवं प्रबंधक (औषधि) को सूचनार्थ प्रेषित। निदेश है कि सूचना का अनुलग्नक सहित अविलंब BMSICL के **website (www.bmsicl.gov.in)** एवं e-proc2 (**www.eproc2.bihar.gov.in**) पर अपलोड करना सुनिश्चित करें।


महाप्रबंधक (अधिप्राप्ति)



TENDER NO. BMSIC/DRUGS/25-02

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name : - PUSHKAR PHARMA Total Number of Pages Submitted in bid documents: - 01 TO 79

Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein.	YES	16	YES	-
2	3.(b)	EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2, as per following table:- S.N. No. of drugs quoted EMD Amount 1 Upto 5 drugs Rs1,00,000/- (One Lakh only) 2 For 6 to 10 Drugs Rs 2,00,000/- (Two Lakh only) 3 For 11 to 15 Drugs Rs 3,00,000/- (Three Lakh only) 4 For 16 to 20 Drugs Rs 4,00,000/- (Four Lakh only) 5 More than 20 Drugs Rs 5,00,000/- (Five Lakh only)	YES	17-21	YES	As per Bid document clause 3(b) BG Submitted for EMD must be Schedule/Nationalized Bank Payable at Patna But firm has not submitted the same.
3	3.(c)	Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	YES	12-14	YES	-
4	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.	YES	69-78	YES	-
5	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	YES	41-43	YES	-
6	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	YES	30	YES	-
7	3.(q)	Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).	YES	03-05	YES	-

Anilana Singh

Beech

19

TENDER NO. BMSIC/DRUGS/25-02

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Pushkar Pharma. Total Number of Pages Submitted in bid documents:- 79

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	55	Yes	
2	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	6-7	Yes	
3	3.(f)	Minimum three years old valid Manufacturing License of the quoted product.	Yes	44-53	Yes	
4		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	44-53	Yes	
5		Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable. Explanation- In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945.	Yes	22-29	No	MSC not submitted for NIT sr. no. 2.
6		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	NA	NA	NA	

17-3-25
24/03/25

12-3-25

14/3/25

JP

7		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.	NA	NA	NA	
8		Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).	Yes	64-67	No	Only application submitted.
9		Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	Yes	44-53	Yes	
10	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA	NA	NA	
11	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.	NA	NA	NA	
12	3.(i)	Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.	Yes	32-37	Yes	
13	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted. Explanation- Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandisthat the GMP certificate should remain valid till the date of submission of tender.	Yes	9	Yes	
14	3.(k)	Maximum Production Capacity Certificate (Section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section (wherever applicable). Self-attested copies are to be submitted. In case of Importer, an affidavit (with Stamp) sworn before first class magistrate/ Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/evidence of import in items of said product with quantity details.	Yes	8	Yes	

26/5

24/03/25

12/3-25

12/13/25

17


TENDER NO. BMSIC/DRUGS/25-02

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Pushkar Pharma. Total Number of Pages Submitted in bid documents:- 79

Sheet to be used for verification of product approval and market standing


Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Dosage Form		Pack Size		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	Approval From	Approved Upto	Approved in Brand /Generic Name	
1	2	Atropine Sulphate	Atropine Sulphate Ophthalmic Solution USP (page no. 49)	1% w/v	Atropine Sulphate IP 1%	Eye drops	Eye drops	5 ml bottle	3ml, 5ml, 10ml, 15ml	09.01.2009	08.01.2029	Generic	Not submitted
2	12	Homatropine	Homatropine Hydrobromide Eye Drops IP (page no. 50)	2%	Homatropine Hydrobromide IP 2%	Drops	Eye drops	5ml	3ml, 5ml, 10ml, 15ml	16.07.2012	08.01.2029	Generic	Submitted (page no. 27)
3	15	Lorazepam	Lorazepam Injection IP (page no. 51)	2 mg/ml	Each ml contains: Lorazepam IP 2 mg	Injection	Injection	1 ml Vial	1ml, 2ml ampoule	25.07.2015	08.01.2029	Generic	Submitted (page no. 28)
4	16	Neostigmine	Neostigmine Injection IP (page no. 53)	0.5 mg/ml	Each ml contains: Neostigmine Methyl sulphate Eq. to Neostigmine 0.5 mg	Injection	Injection	1 ml Ampoule	1ml, 2ml, 5ml, 10ml	18.05.2021	08.01.2029	Generic	Submitted (page no. 25)
5	29	Tropicamide	Tropicamide Eye drop IP (page no. 52)	1%	Tropicamide IP 1%	Drops	Eye drops	15ml	3ml, 5ml, 10ml, 15ml	09.01.2009	08.01.2029	Generic	Submitted (page no. 23)





 12/3/28


 12/3/28



TENDER NO. BMSIC/DRUGS/25-02

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Pushkar Pharma. Total Number of Pages Submitted in bid documents:- 79

Sheet for verification of licence details

Sl. No.	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	2	Atropine Sulphate	25 & 28	MNB.08/28 & S-MB/08/29	NA	NA	09.01.2009	08.01.2029	04.12.2024 (page no. 9)	03.06.2025
2	12	Homatropine	25 & 28	MNB.08/28 & S-MB/08/29	NA	NA	09.01.2009	08.01.2029	04.12.2024 (page no. 9)	03.06.2025
3	15	Lorazepam	25 & 28	MNB.08/28 & S-MB/08/29	NA	NA	09.01.2009	08.01.2029	04.12.2024 (page no. 9)	03.06.2025
4	16	Neostigmine	25 & 28	MNB.08/28 & S-MB/08/29	NA	NA	09.01.2009	08.01.2029	04.12.2024 (page no. 9)	03.06.2025
5	29	Tropicamide	25 & 28	MNB.08/28 & S-MB/08/29	NA	NA	09.01.2009	08.01.2029	04.12.2024 (page no. 9)	03.06.2025

Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/525-2024/11674 dt 04.03.2025 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due deligence and care.Inspite, some inadvertent discreprencies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discreprencies are observed for rectification.

low *nd* *Desk 12/3/25* *Special 12/3/25* *SC*